GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » ROA %

Evoke Pharma (STU:EV00) ROA % : -105.32% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Evoke Pharma's annualized Net Income for the quarter that ended in Dec. 2023 was €-7.29 Mil. Evoke Pharma's average Total Assets over the quarter that ended in Dec. 2023 was €6.92 Mil. Therefore, Evoke Pharma's annualized ROA % for the quarter that ended in Dec. 2023 was -105.32%.

The historical rank and industry rank for Evoke Pharma's ROA % or its related term are showing as below:

STU:EV00' s ROA % Range Over the Past 10 Years
Min: -166.2   Med: -104.57   Max: -65.88
Current: -85.08

During the past 13 years, Evoke Pharma's highest ROA % was -65.88%. The lowest was -166.20%. And the median was -104.57%.

STU:EV00's ROA % is ranked worse than
91.67% of 1081 companies
in the Drug Manufacturers industry
Industry Median: 1.68 vs STU:EV00: -85.08

Evoke Pharma ROA % Historical Data

The historical data trend for Evoke Pharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma ROA % Chart

Evoke Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -119.52 -160.06 -88.31 -75.57 -80.88

Evoke Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.05 -81.51 -78.08 -81.14 -105.32

Competitive Comparison of Evoke Pharma's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoke Pharma's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's ROA % distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's ROA % falls into.



Evoke Pharma ROA % Calculation

Evoke Pharma's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-7.145/( (11.187+6.482)/ 2 )
=-7.145/8.8345
=-80.88 %

Evoke Pharma's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-7.288/( (7.358+6.482)/ 2 )
=-7.288/6.92
=-105.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Evoke Pharma  (STU:EV00) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-7.288/6.92
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-7.288 / 6.148)*(6.148 / 6.92)
=Net Margin %*Asset Turnover
=-118.54 %*0.8884
=-105.32 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Evoke Pharma ROA % Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma (STU:EV00) Business Description

Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines